Einsenca Inc.
Kennett Square, PA
- UEI
- J2PGQ6JNTVS9
- CAGE
- 971K2
- Primary NAICS
- 325412 Pharmaceutical Preparation Manufacturing
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- SAM.gov registration date
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Modulo Bio, Inc. | San Diego, CA | — |
| Mtti | West Chester, PA | 325413 In-Vitro Diagnostic Substance Manufacturing |
| Artery Therapeutics, Inc. | San Ramon, CA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Rosalind Franklin University Of Medicine & Science | North Chicago, IL | 611310 Colleges, Universities, and Professional Schools |
| Seattle Institute For Biomedical And Clinical Research | Seattle, WA | 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
About the company
Einsenca Inc., a for-profit biomedical research company based in Kennett Square, Pennsylvania, is a federal research grant recipient focused on translational imaging science and neuroinflammation diagnostics, operating exclusively as a prime recipient with no subcontracting footprint across its recent federal award portfolio.
Einsenca's federal work centers on the development of myeloperoxidase-targeting positron-emission-tomography (PET) and magnetic-resonance-imaging (MRI) agents for visualizing inflammatory disease activity in neurodegenerative disease. The company holds three federal research grants awarded across the past four years. In September 2026, the Defense Health Agency awarded Einsenca $3.5 million under the Military Medical Research and Development program (CFDA 12.420) to translate an MPO-sensing MRI agent for visualizing inflammatory disease activity in multiple sclerosis, with work performed at Leipsic, Delaware and running through August 2030. In July 2025, the National Institute on Aging awarded a project grant for a Phase 0 study evaluating in vivo characteristics of a myeloperoxidase-targeting PET agent (18F-EH301) in healthy volunteers and early Alzheimer's disease patients through June 2027. In September 2022, the National Institute on Aging also awarded a project grant for PET imaging of damaging neuroinflammation in Alzheimer's disease, with ultimate completion in August 2026. Combined federal grant funding across all three awards totals $12.8 million obligated. Customer concentration is split between the National Institute on Aging (two awards) and the Defense Health Agency (one award), covering 100% of recent activity. One award reaches ultimate completion within the next twenty-four months and faces renewal or recompete by August 2026.
Quick answers
Is Einsenca Inc. registered in SAM.gov?
Yes. Einsenca Inc.'s SAM.gov registration is active through September 28, 2027.
What is Einsenca Inc.'s CAGE code?
Einsenca Inc.'s CAGE code is 971K2, and its Unique Entity ID (UEI) is J2PGQ6JNTVS9.
What is Einsenca Inc.'s most recent federal award?
Einsenca Inc.'s most recent federal grant award is Translation of MPO-sensing MRI agent to visualize inflammatory disease activity in multiple sclerosis (HT9425261E411), from Defense Health Agency, on July 29, 2026.
On GovTribe
See Einsenca Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors